The urokinase-type plasminogen activator system in cancer and other pathological conditions: Introduction and perspective

Current Pharmaceutical Design

Volumn 9, Issue 19, 2003, Pages

  Rosenberg, Steven ^a  

^a XDx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE RECEPTOR;

BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EDITORIAL; EXTRACELLULAR MATRIX; FIBRINOLYSIS; GENE EXPRESSION REGULATION; HUMAN; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION;

EID: 0037530469     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (37)

1. McCawley, L. J.; Matrisian, L. M. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 2001, 13, 534-40.
2. Skiles, J. W.; Monovich, L. G.; Jeng, A. Y., Matrix Metalloproteinase Inhibitors for Treatment of Cancer, in Annual Reports Med. Chem., A.M. Doherty, Editor. 2000, Academic Press: San Diego. p. 167-176.
3. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer trials and tribulations. Science 2002, 295, 2387-92.
4. Carmeliet, P.; Collen, D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb. Res. 1998, 91, 255-285.
5. Carmeliet, P.; Moons, L.; Dewerchin, M.; Rosenberg, S.; Herbert, J. M.; Lupu, F.; Collen, D. Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J. Cell Biol. 1998, 140, 233-45.
6. Liu, S.; Aaronson, H.; Mitola, D. J.; Leppla, S. H.; Bugge, T. H. Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc. Natl. Acad. Sci. USA 2003, 13, 13.
7. Zhou, H. M.; Nichols, A.; Meda, P.; Vassalli, J. D. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J. 2000, 19, 4817-26.
8. Bauvois, B. Transmembrane proteases in focus: diversity and redundancy? J. Leukoc. Biol. 2001, 70, 11-7.
9. Hooper, J. D.; Clements, J. A.; Quigley, J. P.; Antalis, T. M. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J. Biol. Chem. 2001, 276, 857-60.
10. Andreasen, P. A.; Kjoller, L.; Christensen, L.; Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 1997, 72, 1-22.
11. Andreasen, P. A.; Egelund, R.; Petersen, H. H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol. Life Sci. 2000, 57, 25-40.
12. Look, M. P.; Van Putten, W. L.; Duffy, M. J.; Harbeck, N.; Christensen, I. J.; Thomssen, C.; Kates, R.; Spyratos, F.; Ferno, M.; Eppenberger-Castori, S.; Sweep, C. G.; Ulm, K.; Peyrat, J. P.; Martin, P. M.; Magdelenat, H.; Brunner, N.; Duggan, C.; Lisboa, B. W.; Bendahl, P. O.; Quillien, V.; Daver, A.; Ricolleau, G.; Meijer-Van Gelder, M. E.; Manders, P.; Fiets, W. E.; Blankenstein, M. A.; Broet, P.; Romain, S.; Daxenbichler, G.; Windbichler, G.; Cufer, T.; Borstnar, S.; Kueng, W.; Beex, L. V.; Klijn, J. G.; O'Higgins, N.; Eppenberger, U.; Janicke, F.; Schmitt, M.; Foekens, J. A. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. 2002, 94, 116-28.
13. Janicke, F.; Prechtl, A.; Thomssen, C.; Harbeck, N.; Meisner, C.; Untch, M.; Sweep, C. G.; Selbmann, H. K.; Graeff, H.; Schmitt, M. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl. Cancer Inst. 2001, 93, 913-20.
14. Frandsen. T. L.; Holst-Hansen, C.; Nielsen, B. S.; Christensen, I. J.; Nyengaard, J. R.; Carmeliet, P.; Brunner, N. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Cancer Re.s 2001, 61, 532-7.
15. Tressler, R. J.; Pitot, P. A.; Stratton, J. R.; Forrest, L. D.; Zhuo, S.; Drummond, R. J.; Fong, S.; Doyle, M. V.; Doyle, L. V.; Min, H. Y.; Rosenberg, S. Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth. APMIS 1999, 107, 168-173.
16. Klinghofer, V.; Stewart, K.; Mcgonigal, T.; Smith, R.; Sarthy, A.; Nienaber, V.; Butler, C.; Dorwin, S.; Richardson, P.; Weitzberg, M.; Wendt, M.; Rockway, T.; Zhao, X.; Hulkower, K. I.; Giranda, V. L. Species Specificity of Amidine-Based Urokinase Inhibitors. Biochemistry 2001, 40, 9125-9131.
17. Appella, E.; Ullrich, S. J.; Stoppelli, M. P.; Corti, A.; Cassani, G.; Blasi, F. The Receptor-binding Sequence of Urokinase: A biological function for the growth-factor module of proteases. J.Biol.Chem. 1987, 262, 4437-4440.
18. Stepanova, V. V.; Tkachuk, V. A. Urokinase as a multidomain protein and polyfunctional cell regulator. Biochemistry. (Mosc) 2002, 67, 109-18.
19. Ploug, M. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site. Biochemistry 1998, 37, 16494-505.
20. Li, H.; Griscelli, F.; Lindenmeyer, F.; Opolon, P.; Sun, L. Q.; Connault, E.; Soria, J.; Soria, C.; Perricaudet, M.; Yeh, P.; Lu, H. Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice. Hum. Gene Ther. 1999, 10, 3045-53.
21. Min, H. Y.; Doyle, L. V.; Vitt, C. R.; Zandonella, C. L.; Stratton-Thomas, J. R.; Shuman, M. A.; Rosenberg, S. Urokinase Receptor Antagonists Inhibit Angiogenesis and Primary Tumor Growth in Syngeneic Mice. Cancer Res. 1996, 56, 2428-2433.
22. Bajou, K.; Noel, A.; Gerard, R. D.; Masson, V.; Brunner, N.; Holst-Hansen, C.; Skobe, M.; Fusenig, N. E.; Carmeliet, P.; Collen, D.; Foidart, J. M. Absence of host plasminogen activator inhibitor I prevents cancer invasion and vascularization. Nature Med. 1998, 4, 923-8.
23. McMahon, G. A.; Petitclerc, E.; Stefansson, S.; Smith, E.; Wong, M. K.; Westrick, R. J.; Ginsburg, D.; Brooks, P. C.; Lawrence, D. A. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J. Biol. Chem. 2001, 276, 33964-8.
24. Waltz, D. A.; Fujita, R. M.; Yang, X.; Natkin, L.; Zhuo, S.; Gerard, C. J.; Rosenberg, S.; Chapman, H. A. Nonproteolytic role for the urokinase receptor in cellular migration in vivo. Am. J. Respir. Cell Mol. Biol. 2000, 22, 316-22.
25. Gyetko, M. R.; Sud, S.; Kendall, T.; Fuller, J. A.; Newstead, M. W.; Standiford, T. J. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeroginosa infection. J. Immunol. 2000, 165, 1513-1519.
26. Rijneveld, A. W.; Levi, M.; Florquin, S.; Speelman, P.; Carmeliet, P.; Van Der Poll, T. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J. Immunol. 2002, 168, 3507-11.
27. Simon, D. I.; Wei, Y.; Zhang, L.; Rao, N. K.; Xu, H.; Chen, Z.; Liu, Q.; Rosenberg, S.; Chapman, H. A. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J. Biol. Chem. 2000, 275, 10228-34.
28. Wei, Y.; Eble, J. A.; Wang, Z.; Kreidberg, J. A.; Chapman, H. A. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol. Biol. Cell 2001, 12, 2975-86.
29. Fong, S.; Doyle, M. V.; Goodson, R. J.; Drummond, R. J.; Stratton, J. R.; McGuire, L.; Doyle, L. V.; Chapman, H. A.; Rosenberg, S. Random peptide bacteriophage display as a probe for urokinase receptor ligands. Biol. Chem. 2002, 383, 149-58.
30. Aguirre Ghiso, J. A.; Kovalski, K.; Ossowski, L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 1999, 147, 89-104.
31. Van Der Pluijm, G.; Sijmons, B.; Vloedgraven, H.; Van Der Bent, C.; Drijfhout, J.-W.; Verheijen, J. H.; Quax, P. H.; Karperien, M.; Papapoulos, S.; Lowik, C. Urokinase-Receptor/Integrin Complexes are Functionally Involved in Adhesion and Progression of Human Breast Cancer in Vivo. Am. J. Pathol. 2001, 159, 971-982.
32. Blasi, F.; Carmeliet, P. uPAR: a versatile signalling orchestrator. Nature Rev. Mol. Cell Biol. 2002, 3, 932-43.
33. Rockway, T.W. and Giranda, V.L. Inhibitors of the Proteolytic Activity of Urokinase Type Plasminogen Activator. Curr. Pharm. Des. 2003, 9(19), 1483-1498.
34. Ploug, M. Structure-Function Relationships in the Interaction Between the Urokinase-Type Plasminogen Activator and Its Receptor. Curr. Pharm. Des. 2003, 9(19), 1499-1528.
35. Reuning. U., Sperl, S., Kopitz, C., Kessler, H., Krüger, A., Schmitt, M. and Magdolen, V. Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA/uPAR Interaction and their Effects In Vitro and In Vivo. Curr. Pharm. Des. 2003. 9(19), 1529-1543.
36. Stefansson S., McMahon G.A., Petitclerc, E. and Lawrence, D.A. Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling. Curr. Pharm. Des. 2003, 9(19), 1545-1564.
37. Kugler, M.C., Wei, Y. and Chapman H.A. Urokinase Receptor and Integrin Interactions. Curr. Pharm. Des. 2003, 9(19), 1565-1574.